HB-EGF AND ITS RECEPTORS

HB-EGF是一种膜锚定的促细胞生长因子，被分解释放成熟的HB-EGF，是平滑肌细胞（SMC）的一种有效的促分裂剂和趋化因子。HB-EGF活性由两种受体ErbB 1和ErbB 4介导。在大多数情况下，HB-EGF在体内的功能还没有得到很好的表征。在第一个目标中，SMC衍生的HB-EGF在介导血管中SMC-EC相互作用中的作用将在体内和体外进行研究。此外，将在转基因小鼠体内分析跨膜和成熟HB-EGF作用的潜在差异。第二个目标涉及新的HB-EGF受体的表征。一种是最近纯化和克隆的140 kDa蛋白，其特异性结合HB-EGF，并且作为可溶性受体是特异性HB-EGF拮抗剂。此外，两种新的ErbB 4亚型，一种在质膜结构域中具有不能脱落的改变，另一种缺乏PI 3-激酶结合位点并且不能激活PI 3-激酶活性，将被进一步表征。这些关于HB-EGF功能和受体的研究是重要的，因为HB-EGF被认为有助于正常的生理反应，如伤口愈合和病理过程，如动脉粥样硬化和肺动脉高压。该提案的具体目标是：1。研究HB-EGF在血管中的作用，包括：a）分析HB-EGF启动子-lacZ报告基因在转基因小鼠血管中的时间和空间表达，B）分析HB-EGF对体外EC-SMC相互作用的影响，c）转基因小鼠血管中成熟、跨膜和不可切割的跨膜形式的过度表达，d）HB-EGF启动子-lacZ报告基因在转基因小鼠血管中的表达，e）HB-EGF启动子-lacZ报告基因在转基因小鼠血管中的表达，d）HB-EGF启动子-lacZ报告基因在转基因小鼠血管中的表达，e）HB-EGF启动子-lacZ报告基因在转基因小鼠血管中的表达。d）通过缺失跨膜和胞质结构域，产生仅表达成熟HB-EGF的转基因小鼠。2.表征新型HB-EGF受体，包括：a）新型特异性140 kDa HB-EGF受体的结构和功能分析; B）新型可变剪接ErbB 4亚型的表征，其在跨膜结构域和PI-3 K结合结构域上不同。

HB-EGF is synthesized as a membrane-anchored juxtacrine growth factor that is shred to released mature HB-EGF, a potent mitogen and chemotactic factor for smooth muscle cells (SMC). HB-EGF activity is mediated by two receptors, ErbB1 and ErbB4. For the most part HB-EGF function in vivo is not well characterized. In the first aim the role of SMC-derived HB-EGF in mediating SMC-EC interactions in blood vessels will be examined in vivo and in vitro. In addition, potential differences in the roles of transmembrane and mature HB-EGF will be analyzed in vivo in transgenic mice. The second aim involves characterization of novel HB-EGF receptors. One is a 140 kDa protein that has been recently purified and cloned, binds HB-EGF specifically and as a soluble receptor is a specific HB-EGF antagonist. In addition, two novel ErbB4 isoforms, one with an alteration in the juxtamembrane domain that can not be shed and one that lacks the PI3-kinase binding site and can not activate PI3-kinase activity will be further characterized. These proposed studies on HB-EGF function and receptors are significant since HB-EGF has been suggested to contribute to normal physiological responses such as wound healing and pathological processes such as atherosclerosis and pulmonary hypertension. The Specific Aims of the proposal are: 1. To Investigate the Role of HB-EGF in Blood Vessels including: a) analysis of temporal and spatial HB-EGF promoter-lacZ reporter gene expression in blood vessels of transgenic mice; b) analysis of the effects of HB-EGF on EC-SMC interactions in vitro; c) over- expression of mature, transmembrane and non-cleavable transmembrane forms in the blood vessels of transgenic mice; d) generation of transgenic mice expressing mature HB-EGF only, by deleting the transmembrane and cytoplasmic domains. 2. To Characterize Novel HB-EGF Receptors including: a) Structure and functional analysis of a novel specific 140 kDa HB-EGF receptor; b) characterization of novel alternatively spliced ErbB4 isoforms differing in the juxtamembrane domain and the PI-3K binding domains.